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Cognitive impairment is a core feature of schizophrenia 
but there is limited understanding of the genetic relation-
ship between cognition in the general population and schizo-
phrenia. We examine how common variants associated with 
schizophrenia en masse contribute to childhood cognitive 
ability in a population-based sample, and the extent to which 
common genetic variants associated with childhood cogni-
tion explain variation in schizophrenia. Schizophrenia poly-
genic risk scores were derived from the Psychiatric Genomics 
Consortium (n = 69 516) and tested for association with IQ, 
attention, processing speed, working memory, problem solv-
ing, and social cognition in over 5000 children aged 8 from 
the Avon Longitudinal Study of Parents and Children birth 
cohort. Polygenic scores for these cognitive domains were 
tested for association with schizophrenia in a large UK schizo-
phrenia sample (n = 11 853). Bivariate genome-wide com-
plex trait analysis (GCTA) estimated the amount of shared 
genetic factors between schizophrenia and cognitive domains. 
Schizophrenia polygenic risk score was associated with lower 
performance IQ (P  =  .001) and lower full IQ (P  =  .013). 
Polygenic score for performance IQ was associated with 
increased risk for schizophrenia (P  =  3.56E-04). Bivariate 
GCTA revealed moderate genetic correlation between schizo-
phrenia and both performance IQ (rG = −.379, P = 6.62E-05) 
and full IQ (rG = −.202, P = 5.00E-03), with approximately 
14% of the genetic component of schizophrenia shared with 
that for performance IQ. Our results support the presence 
of shared common genetic factors between schizophrenia and 
childhood cognitive ability. We observe a genetic relationship 
between schizophrenia and performance IQ but not verbal IQ 
or other cognitive variables, which may have implications for 
studies utilizing cognitive endophenotypes for psychosis.
Key words:  schizophrenia/cognition/performance 
IQ/polygenic scoring/bivariate heritability
Introduction
Schizophrenia is a severe psychiatric disorder character-
ized by positive symptoms such as delusions and hallucina-
tions, and negative symptoms such as avolition and apathy. 
Deficits in cognitive ability are common and are strong 
predictors of functional outcome,1 but are largely refrac-
tory to current treatments. Cognitive impairments often 
manifest premorbidly during childhood and adolescence,2 
with the largest effects observed for IQ.3,4 These deficits 
persist into adulthood, typically worsen with illness onset 
but thereafter remain relatively static.5 The Measurement 
and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS)6 initiative identified 7 sepa-
rable domains showing deficits in schizophrenia: attention, 
processing speed, reasoning/problem solving, social cogni-
tion, verbal learning, visual learning and working memory.
There is long-standing debate about the degree of 
genetic overlap between cognition in the general popu-
lation and schizophrenia. The proportion of the pheno-
typic correlation between cognition and schizophrenia 
that is due to shared genetic effects was found to be sub-
stantial in a number of twin studies,7–9 although estimates 
of the genetic variance for schizophrenia that was shared 
with cognition varied substantially. In the only twin study 
that was population-based rather than ascertained by 
case status, and which therefore used a measure of cog-
nition that was ascertained premorbidly, only 7% of the 
genetic variance for psychosis was shared with cognition,9 
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compared to 21%–56% in the other studies.7,8 Therefore 
the extent to which cognitive ability and schizophrenia 
share genetic aetiology remains uncertain. With recent 
advances in genetic technology and analytic approaches, 
it is now possible to investigate the underlying genetic 
architecture of complex traits in large cohorts of unre-
lated individuals.
One such approach for doing this is to use polygenic 
score analysis in which a score representing the additive 
effect of large numbers of independent (ie, in approximate 
linkage equilibrium) single nucleotide polymorphisms 
(SNPs) that are associated with 1 trait also contribute to 
the same or a different trait in an independent sample. 
Three previous studies have investigated the relationship 
between cognition in population samples and schizo-
phrenia using polygenic score analysis. Increased poly-
genic risk of schizophrenia was weakly associated with 
lower general cognitive ability,10,11 and with a decline 
in cognitive ability across the lifespan.10 However these 
results have not been consistently replicated12 and poly-
genic risk scores for schizophrenia explained only a small 
proportion of variance in cognition (R2 ≈ 1%). A reverse 
approach showed polygenic scores for general cognition 
(“g”) were associated with schizophrenia, but explained a 
small proportion of variance (R2 < 0.5%).11 These studies 
all focused predominantly on “g” derived from different 
cognitive measures across multiple participating centers. 
To our knowledge, no studies to date have examined 
the genetic overlap between schizophrenia and a range 
of cognitive domains. This study aims to quantify the 
polygenic overlap between schizophrenia and individual 
cognitive domains and thus inform the debate about the 
strength of their genetic relatedness.
A second approach for investigating the underlying 
genetic architecture of complex traits is to use Genome-
wide Complex Trait Analysis (GCTA) to estimate the 
proportion of phenotypic variance explained by com-
mon SNPs across the genome.13 It does this by first 
determining the degree of genetic relatedness between 
all individuals and then estimating the proportion of 
phenotypic variance explained by the genetic relatedness 
matrix using mixed-model analysis.13 The bivariate exten-
sion of GCTA allows quantification of the shared com-
mon genetic factors between 2 traits by determining the 
genetic variance of each trait as well as the genetic covari-
ance, and then calculating the genetic correlation.14 This 
method has been applied previously to show significant 
shared common genetic aetiology between different psy-
chiatric disorders.15 No previous studies have used bivari-
ate GCTA to examine the amount of shared common 
genetic factors between cognition and schizophrenia.
In this study we use data from the largest schizophrenia 
genome-wide association study (GWAS) undertaken to 
date,16 and birth cohort data on a broad range of cog-
nitive phenotypes measured during childhood to under-
take a detailed investigation of the genetic relationship 
between schizophrenia and cognition using both poly-
genic scoring and bivariate GCTA. More specifically, 
we examine (1) whether common variants associated 
with schizophrenia en masse contribute to cognition in 
the general population at age 8, (2) the extent to which 
common genetic variants associated with childhood cog-
nition en masse explain variation in the genetic liability 
to schizophrenia, and (3) the extent to which the pheno-
typic correlation between cognition and schizophrenia is 
explained by common genetic effects.
Methods
Samples
Cognition Samples. The Avon Longitudinal Study 
of  Parents and Children (ALSPAC) is a population-
based birth cohort (http://www.alspac.bris.ac.uk) of, 
initially, 14 062 live births, and has been reported 
extensively.17,18
Phenotype data were collected by ALSPAC when par-
ticipants were 8 years old. Individuals were administered 
the short form Wechsler Intelligence Scale for Children 
(WISC-III)19 (alternate items used for all subtests 
except the coding subtest) as well as 2 additional items 
taken from the Test of Everyday Attention for Children 
(TEACh)20 and the Diagnostic Analysis of Nonverbal 
Accuracy (DANVA).21 Cognitive tests were selected a 
priori based on their correspondence to MATRICS 
domains as we have previously reported.22 The follow-
ing tasks were selected from the WISC-III, with their 
representative cognitive constructs in parentheses: cod-
ing (processing speed), digit span backward (working 
memory), and block design (problem solving). As a 
measure of verbal learning, we used the total number of 
nonwords correctly recalled from an adapted version of 
the Nonword Repetition Test.23 From the TEACh, the 
Sky Search task adjusted for motor speed was selected 
as our measure of attention. The DANVA was used to 
create a social cognition variable by totaling number of 
errors (incorrect assignment of emotions) across all 4 
emotional domains. The selection of cognitive tests and 
corresponding domains mirrored previous work using 
these samples.22 We also used WISC IQ scores for verbal, 
performance and full IQ. The number of individuals with 
genotype and phenotype information in ALSPAC varied 
by specific test and ranged from 5109 to 5556 (supple-
mentary table 2).
Further details on the ALSPAC sample including 
descriptive information about the cognitive variables, 
genotyping and imputation procedures can be found in 
supplementary text and supplementary tables 1 and 2.
Schizophrenia Samples. Two independent schizophrenia 
samples were used as training datasets: the Schizophrenia 
Working Group of the Psychiatric Genetics Consortium 
(PGC-SCZ) and CLOZUK. The PGC-SCZ is a 
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collaborative effort across multiple centers with the aim 
of using large sample sizes to uncover novel findings in 
genetic analyses. The majority of samples in PGC-SCZ 
have a European ancestry. Information regarding indi-
vidual samples and QC can be found elsewhere.16 We use 
data from the CLOZUK sample as a replication data-
set and therefore these individuals (cases and controls) 
were omitted from the PGC-SCZ sample for our primary 
analyses.
We further used CLOZUK as the testing dataset in 
the polygenic score analysis assessing the extent to which 
common genetic variants associated with childhood cog-
nition explain variation in the genetic liability to schizo-
phrenia, and in the bivariate GCTA. It was not possible 
to use the PGC-SCZ sample for this analysis given the 
lack of availability of genotype data and the requirement 
for this data in these analyses.
CLOZUK constitutes individuals with schizophre-
nia who were prescribed clozapine and received a clini-
cian diagnosis of treatment resistant of schizophrenia. 
It has been demonstrated through a variety of differ-
ent analyses that genetic risk factors for this sample are 
very similar to conventionally ascertained schizophrenia 
samples, including their frequency of CNVs,24 sign test 
for schizophrenia associated loci,25 and amount of com-
mon polygenic risk which aligns with other schizophrenia 
samples.16 Therefore the genetic risk factors and patterns 
of association indicate this is a highly valid schizophrenia 
sample for these types of genetic interrogations.
GWAS summary statistics were available for the com-
plete PGC-SCZ sample minus individuals from the 
CLOZUK sample (termed PGC-SCZ hereafter), total-
ing 29 415 schizophrenia cases and 40 101 controls. The 
CLOZUK sample consists of 5554 cases and 6299 con-
trols and has been described elsewhere.16
Additional information about the schizophrenia sam-
ples and genotyping can be found in supplementary text.
Statistical Analysis
Polygenic Score Analyses. Polygenic score methodol-
ogy follows the procedure described by the schizophre-
nia PGC.26 For all analyses, SNPs were removed if  they 
had a low minor allele frequency (MAF < 0.01), and were 
subsequently pruned for linkage disequilibrium using the 
clumping function (--clump) in PLINK27 removing SNPs 
within 500kb (--clump-kb) and r2 > .25 (--clump-r2) with 
a more significantly associated SNP. We used the --score 
command in PLINK to calculated polygenic scores.27 
Five P-value thresholds (PT < .0001, .01, .1, .3, .5) for 
SNP association were used.
Polygenic Risk Scores for Schizophrenia. Genotypes 
were tested for association with schizophrenia in the 2 
independent schizophrenia case/controls samples (1) 
PGC-SCZ and (2) CLOZUK.16 Polygenic scores were 
calculated by summing the number of susceptibility 
alleles of each index SNP weighted by the logarithm of 
the SNP odds ratios. Polygenic risk scores for schizophre-
nia were calculated for each individual in the ALSPAC 
sample and linear regressions were used to test whether 
these scores were associated with performance on cog-
nitive tasks. Consistent with previous analyses using 
the ALSPAC sample, no covariates were included in 
the polygenic analysis as ALSPAC has previously been 
shown to have no significant population stratification.28 
We compared our original results against the results of 
10 000 permutations where cognitive scores in ALSPAC 
individuals were randomly shuffled (supplementary text).
Polygenic Risk Scores for Cognition. Genotypes were 
tested for association with the cognitive phenotypes 
in ALSPAC using linear regression under an additive 
genetic model in PLINK.27 No covariates were used in 
the analysis, as an EIGENSTRAT analyses did not 
reveal any significant population stratification. Analyses 
were run using the --standard-beta command in PLINK. 
Polygenic scores were calculated by summing the num-
ber of susceptibility alleles of each index SNP weighted 
by its coefficient of effect. Since genotype information is 
required in the target dataset, we used CLOZUK data for 
this analysis. Polygenic scores for each cognitive domain 
were calculated for each individual in the CLOZUK 
sample and logistic regressions were used to test whether 
the resulting scores were associated with schizophrenia 
case status. Analyses were covaried for 7 population prin-
cipal components for the CLOZUK sample to ensure 
that estimates were not affected by subtle differences in 
population structure. We applied post hoc permutation 
correction for associations reaching nominal levels of 
significance. When applicable, we randomized case/con-
trol status in CLOZUK and repeated logistic regression 
analyses 10 000 times (supplementary text).
Bivariate GCTA. Bivariate GCTA was used to estimate 
the genetic correlation between schizophrenia risk and 
cognitive ability by common SNPs across the genome.14 
GCTA determines the degree of genetic relatedness 
between all individuals and then estimates the proportion 
of phenotypic variance explained by the genetic related-
ness matrix using a mixed-effect model.13 The bivariate 
extension to this approach determines the genetic variance 
of each trait as well as the genetic covariance, and then 
calculates the genetic correlation (the ratio between genetic 
covariance and genetic variance). We applied a stringent 
cut-off for relatedness (proportion of shared genetic 
material <2.5%) and removed 1 individual from each 
genetically related pair.13 Bivariate GCTA was fitted with 
restricted maximum likelihood (REML) based on a linear 
model for the cognitive phenotypes and a disorder-model 
for schizophrenia with lifetime disorder risk set to 1%.29 
A genetic relationship matrix was created for CLOZUK 
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and ALSPAC. The genetic relationship matrix was ana-
lyzed for the genetic correlation (rG) between SNPs affect-
ing schizophrenia case status and cognitive performance 
on the 6 domain tests and 3 IQ measures. The proportion 
of genetic variance (rG
2) shared between schizophrenia and 
each cognitive test was calculated.7,9 As GCTA assesses the 
genetic relationship between individuals, a more rigorous 
correction for population stratification is warranted, there-
fore, 20 principal components were used as covariates.
Results
Polygenic Risk Scores for Schizophrenia: Association 
With Cognition
We examined if  polygenic scores for schizophrenia were 
associated with cognitive performance, with the hypoth-
esis that the schizophrenia risk alleles en masse would 
be associated with decreased cognitive performance. 
Associations with performance, verbal and full IQ are 
presented in table 1 and figure 1, and associations with 
cognitive sub-domains are presented in table  2 and fig-
ure 1. Schizophrenia polygenic risk scores derived from 
PGC-SCZ were associated with lower performance IQ 
in ALSPAC at age 8 (P  =  .001; R2  =  0.19%; PT  =  .5). 
This result was observed at multiple training set P-value 
thresholds and replicated using schizophrenia polygenic 
risk scores derived from the independent CLOZUK sam-
ple (P = .029; R2 = 0.09%; PT = .5).
Evidence of association with other cognitive tests was 
less consistent; eg, increased schizophrenia polygenic risk 
was associated with lower full IQ when training on PGC-
SCZ (P =  .013; R2 = 0.11%; PT =  .5) though not when 
training on CLOZUK. Permuted results were entirely 
consistent with the original regression results (supple-
mentary table 7).
Polygenic Risk Scores for Cognition: Association With 
Schizophrenia Status
We investigated whether genetic variants for cognition 
at age 8 were associated with schizophrenia, with the 
hypothesis that genetic variants associated with lower 
cognitive performance would be associated with increased 
risk for schizophrenia. Performance IQ polygenic score 
derived from ALSPAC was significantly associated with 
schizophrenia case status in CLOZUK (P  =  3.56E-04; 
R2 = 0.08%; PT = .5; table 1 and figure 2). This association 
was seen at all training P-value thresholds. The direc-
tion of effect was consistent with our hypothesis. While 
there was limited evidence of association with process-
ing speed, attention and verbal learning (table 2 and fig-
ure 2), these associations were weaker and less consistent 
across training P-value thresholds than those for perfor-
mance IQ. Permuted results were entirely consistent with 
the original regression results (supplementary table 7).
To provide results for comparison, we performed split 
half  polygenic analysis for cognition within ALSPAC and 
for schizophrenia within the CLOZUK. Furthermore, 
work completed by the Schizophrenia Working Group of 
Psychiatric Genomics Consortium showed that polygenic 
Table 1. Results From Polygenic Scores Analysis for the Global Measures of IQ
Training 
Dataset Testing Dataset PT N SNPs
Performance IQ Verbal IQ Full IQ
D R2 (%) P-value D R2 (%) P-value D R2 (%) P-value
PGC-SCZ 
without 
CLOZUK
ALSPAC 
cognition
.0001 1497 − 0.0556 .079 − 0.0439 .119 − 0.0621 .064
.01 16 721 − 0.112 .013 − 0.0294 .202 − 0.0858 .030
.1 67 032 − 0.212 6.07E-04 − 0.0316 .186 − 0.129 .008
.3 130 553 − 0.201 8.43E-04 − 0.0352 .163 − 0.123 .009
.5 173 932 − 0.188 .001 − 0.0305 .194 − 0.112 .013
CLOZUK 
SCZ
ALSPAC 
cognition
.0001 372 − 0.0306 .193 − 0.026 .416 − 0.011 .221
.01 10 133 − 0.142 .005 + 0.001 .965 − 0.022 .139
.1 58 336 − 0.0715 .047 + 0.021 .458 − 0.007 .486
.3 127 606 − 0.0765 .040 + 0.022 .281 − 0.005 .653
.5 177 080 − 0.0857 .029 + 0.02 .321 − 0.005 .578
ALSPAC 
cognition
CLOZUK SCZ .0001 32 − 0.028 .041 + 0.003 .727 − 0.008 .359
.01 2157 − 0.042 .011 + 0.013 .200 − 0.014 .178
.1 19 870 − 0.09 1.56E-04 + 0.004 .632 − 0.025 .058
.3 50 819 − 0.084 2.70E-04 + 0.004 .611 − 0.016 .140
.5 76 137 − 0.081 3.56E-04 + 0.005 .573 − 0.013 .198
Note: Italicized results are for P-value < .05. ALSPAC, Avon Longitudinal Study of Parents and Children; PGC-SCZ, Schizophrenia 
Working Group of the Psychiatric Genetics Consortium; SNP, single nucleotide polymorphism. Training dataset refers to the dataset 
used to create the polygenic scores and testing dataset is the set tested for prediction. PT refers to the P-value threshold used in the 
training dataset. D is the direction of effect, with negative (−) meaning increased SCZ risk is associated with decreased cognitive 
performance and positive (+) indicating increased SCZ risk is associated with increased cognitive performance. The number of SNPs 
used in the scores for the ALSPAC cognitive to CLOZUK SCZ analyses varied slightly for each cognitive domain, here we reported the 
average but these numbers are reported in full in supplementary table 4.
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risk scores using schizophrenia risk variants derived from 
PGC minus CLOZUK (PGC-SCZ) reliably distinguishes 
between schizophrenia cases and controls in CLOZUK.16 
At a PT =  .05 the variance explained by the PGC-SCZ 
polygenic score was R2 = 0.170 in the CLOZUK sample 
(P-value < 4.26E-269 [P-value reported in article is 0, 
therefore we report it as less than the last nonzero P-value 
reported]). Further details and results are presented in 
supplementary tables 5 and 8 respectively.
Bivariate GCTA
Bivariate GCTA revealed evidence of a common genetic 
overlap between schizophrenia and cognition. The 
genetic correlation (rG) was −.379 (P = 6.62E-05) between 
performance IQ and schizophrenia, and −0.202 between 
full IQ and schizophrenia (P  =  5.00E-03; table  3). The 
negative genetic correlation indicates that alleles associ-
ated with increased schizophrenia risk are associated 
with poorer cognitive function. Thus approximately 14% 
of the genetic component for schizophrenia is shared 
with that for performance IQ measured at age 8 and 4% 
for full IQ (estimated as rG
2). Evidence of genetic shar-
ing was weaker for working memory and schizophrenia 
(rG = −.193; P =  .044), whilst there was no evidence to 
support the presence of shared genetic aetiology with 
schizophrenia for any of the other cognitive domains 
Fig. 1. Proportion of variance in cognitive phenotypes in the Avon Longitudinal Study of Parents and Children (ALSPAC) dataset 
explained by schizophrenia polygenic scores. The upper panel plot uses scores derived from the Schizophrenia Working Group of the 
Psychiatric Genetics Consortium (PGC-SCZ) with CLOZUK omitted (PGC − CLOZUK). The lower panel plot uses scores derived 
from the CLOZUK sample. Two-sided P-values for evidence at P < .05 are displayed. R2 values above 0 reflect direction of effects 
consistent with our hypotheses that schizophrenia polygenic risk is associated with lower cognitive scores; R2 values below 0 reflect 
direction of effects opposite to those hypothesized.
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(table  3). Univariate GCTA results for each phenotype 
can be found in supplementary table 6.
Discussion
We have investigated the relationship between cognition 
and schizophrenia using data from a large population 
sample and multiple independent, large schizophrenia 
datasets. We tested both whether polygenic scores for cog-
nition measured at age 8 were associated with schizophre-
nia and if  SNPs conferring risk for schizophrenia were 
associated with cognitive performance in children at age 
8. We found a consistent, reciprocal relationship between 
SNPs associated with schizophrenia and SNPs associated 
with performance IQ using polygene scoring analysis 
and bivariate GCTA. There was no evidence to support 
genetic overlap between schizophrenia and verbal IQ, and 
hence weaker evidence for full IQ (as this is constructed 
from performance and verbal IQ). The finding that the 
genetic overlap between cognition and schizophrenia is 
strongest for performance IQ is noteworthy and should 
inform endophenotype research strategies particularly 
given previous findings that performance IQ is compro-
mised when compared to verbal IQ in patients and their 
relatives.30,31 Little evidence was found to support genetic 
overlap between schizophrenia and other specific cogni-
tive domains using either the polygenic score analysis or 
bivariate GCTA.
In order to quantify the genetic overlap between 
schizophrenia and cognition, we used the genetic cor-
relation (rG), which indexes the correlation between 
genetic effects of  2 phenotypes. The genetic correlation 
between full IQ and schizophrenia that we observed 
using bivariate GCTA (rG = −.202) was smaller than esti-
mated through 2 twin studies that identified twin pairs 
on the basis of  their case status and measurements of 
cognition post onset of  schizophrenia (rG  =  −.75 and 
rG = −.46, respectively). It should be noted that our esti-
mates are based only on variants tagged by common 
SNPs13 and that these comparisons are limited by differ-
ences in cognitive measures used, sample ascertainment 
strategies, and differing study designs. Despite this our 
findings align well with a population-based twin study 
that reported a genetic correlation between psychosis 
and premorbidly-assessed full IQ of −0.26.9 The similar 
association between IQ and schizophrenia across differ-
ent co-relative groups reported in a recent population-
based study also suggests that shared genetic effects are 
likely to be very modest.32
Our results partially replicate previous work investigat-
ing the genetic overlap between schizophrenia and cog-
nition using polygenic score analysis that focused solely 
on full IQ or on “g.”11,12 The amount of variance in full 
IQ explained by schizophrenia polygenic risk in our study 
(R2 ~ 0.1%) is lower than reported for “g” (R2 ~ 0.5% 
to 1%) even though our training dataset was substan-
tially larger.11 Our study was equivalent in terms of the 
size of the cognitive datasets, but all studies to date are 
likely to have been underpowered to accurately measure 
genetic effects on cognition,12 which might explain why 
results across studies are inconsistent in estimating effect 
sizes.33 It is also possible that our study differs from previ-
ous studies in terms of differences in the cognitive tests 
used or age at which the cognitive tests were assessed. 
Nevertheless, it is apparent that the magnitude of the 
overlapping polygenic signal between schizophrenia and 
Fig. 2. Proportion of variance in schizophrenia explained by polygenic scores of alleles associated with different cognitive phenotypes 
within the Avon Longitudinal Study of Parents and Children (ALSPAC) sample. The figure plots polygenic scores derived from ALSPAC 
cognitive phenotypes tested in the CLOZUK schizophrenia sample. Two-sided P-values for evidence at P < .05 are displayed. R2 values 
above 0 reflect direction of effects consistent with our hypotheses that polygenic risk for lower cognition scoring is associated with higher 
schizophrenia risk; R2 values below 0 reflect direction of effects opposite to those hypothesized.
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cognition is modest, as measured by different studies 
to date.
As heritability of IQ increases throughout childhood 
and early adolescence,34,35 it may be that genetic effects 
are contributing to cognition to a lesser extent in our 
study, which assessed cognition during childhood, than 
in previous studies that assessed cognition during adult-
hood. However, GCTA estimates of common genetic fac-
tors contributing to IQ in childhood are still substantial 
(hSNP
2  ranging from 0.22 to 0.46)36 and we observe similar 
estimates in the present study (table 3 for hSNP
2  for cogni-
tive test in ALSPAC). Furthermore, these estimates are 
similar to those from twin studies (h2 = 0.41).37
Implications
Our comprehensive approach to investigating common 
genetic architecture across cognition and schizophre-
nia leads us to 3 important observations. First, whilst 
genetic effects are shared between cognition measured 
at age 8 and schizophrenia this is primarily with per-
formance IQ, implicating fluid rather than crystallized 
intelligence.38 Despite evidence of shared genetic effects 
between performance IQ and schizophrenia, the extent 
to which common SNPs explain variation in these phe-
notypes is modest. While there was a sizeable genetic 
correlation between schizophrenia and performance IQ 
(rG = −.38 ± 0.11 SE), this is smaller (though less precisely 
estimated) than that reported between schizophrenia and 
major depressive disorder (rG = .43 ± 0.06 SE), and sub-
stantially smaller than between schizophrenia and bipo-
lar disorder (rG  =  .68 ± 0.04 SE), although higher than 
several other neuropsychiatric disorders.15
Second, most cognitive measures that we examined, 
which map onto the MATRICS domains, show little or 
no evidence of genetic overlap with schizophrenia. If  this 
is replicated in other studies, it will call into question their 
use as endophenotypes. Thirdly the fact that cognition 
measured in a general population sample at age 8 shows 
genetic overlap with schizophrenia provides support for 
a genetic contribution to the neurodevelopmental nature 
of schizophrenia.
Endophenotypes as originally conceived were seen as 
aiding gene discovery for phenotypes such as schizophre-
nia. Our results, together with those in adult populations, 
suggest cognitive measures will have limited utility in this 
sense. A  more productive approach may be to leverage 
the genetic overlap between cognition and schizophrenia 
by using cognition as a stratifier in schizophrenia discov-
ery GWAS.39
It is possible that our findings of limited genetic shar-
ing reflect the fact that we have only examined the effects 
of single common genotyped variants that collectively 
explain limited heritability or that measures used to date 
do not adequately capture aspects of cognition that are 
most relevant to the genetic aetiology of schizophrenia. Ta
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For example, cognitive models of psychosis suggest that 
deficits in source monitoring, reasoning biases and pre-
dictive error processing may play key roles in the aetiol-
ogy of psychotic experiences, and provide an explanatory 
link between altered biological processes and psychopa-
thology.40–42 Whilst numerous studies have measures of 
cognitive ability related to IQ, working memory, process-
ing speed and attention, very few studies have measures 
that directly capture deficits in the cognitive models of 
psychosis described above. If  these show greater merit 
as endophenotypes for schizophrenia than currently 
assessed cognitive domains, their value will most likely 
be in helping to understand the mechanisms mediating 
genetic risk for schizophrenia as identified through large-
scale collaborative genome-wide enterprises (eg, recent 
genome-wide evidence of association for over 100 SNPs 
for schizophrenia from a consortium of >35 000 cases).16
Strengths and Limitations
Our study has many strengths including use of the 
world’s largest schizophrenia dataset, a large and rela-
tively homogenous population based sample for assessing 
cognition, and use of cognitive sub-domains as well as 
general IQ measures. Furthermore, we assess the genetic 
relationship between schizophrenia and cognition using 2 
different complementary approaches, polygenic analysis 
and bivariate GCTA. One of the main limitations of our 
study is that despite the use of one of the largest popula-
tion-based birth cohorts worldwide with the required cog-
nitive and genetic data, this sample may be too small to 
serve as a training dataset for deriving polygenic scores of 
cognitive phenotypes. However, to our knowledge, this is 
the largest homogenous collection of childhood cognitive 
data available currently. Furthermore, we have used only 
cognitive data measured during childhood and are not 
able to examine the possible influence of varying herita-
bility at different ages, although our results using GCTA 
provide evidence that cognition at age 8 clearly has a sub-
stantial common genetic component. It is challenging to 
make comparisons between variance explained in “within 
trait” analyses (such as that presented in supplementary 
tables 5 and 8) and the primary cross-trait analyses we 
present between schizophrenia and cognition, particularly 
given the difference in power between samples. Such com-
parisons will be aided by equivalent studies conducted 
in very large cognitive datasets in which the phenotypic 
variance explained by common GWAS variants reaches 
a plateau as has begun to be observed in the PGC-SCZ 
datasets.16 A potential limitation is that we cannot iden-
tify individuals in the ALSPAC sample that will develop 
schizophrenia, and that these individuals may bias the 
results. However, this would apply to less than 1% of 
the ALSPAC sample and given the normal distribution 
of polygenic scores for schizophrenia and cognition it 
seems inconceivable that they would explain the observed 
results. Another limitation is that rare genetic variants are 
not captured by GWAS, and therefore do not contribute 
to our estimates; we are therefore capturing the lower 
bound estimate of the genetic overlap between cognition 
and schizophrenia. Individuals with lower cognition were 
also more likely to have missing genetic data (supplemen-
tary table  3), thus our estimates of the genetic overlap 
between schizophrenia and cognition is likely to be con-
servative. A final limitation is that we conducted tests at 
multiple P-value thresholds across cognitive outcomes. 
Whilst there is no established methodology for correcting 
for such correlated polygenic tests we did confirm nomi-
nally significant results with permutation. Significant 
associations between schizophrenia and performance IQ 
were observed in both polygenic score and GCTA analy-
ses and we feel this is unlikely to have arisen due to type 
I error resulting from multiple testing.
In conclusion, we have undertaken a detailed examination 
of the common genetic architecture across cognition and 
schizophrenia. Our results show the relationship between 
schizophrenia and performance IQ is in part due to shared 
common genetic factors, and that this relationship is evident 
using a childhood cognitive sample. Our results suggest that 
identifying genetic factors underlying cognitive endopheno-
types will capture only modest proportions of schizophre-
nia genetic risk. The true value of cognitive endophenotypes 
may lie in helping to understand the mechanisms mediating 
the relationship between genes and disorder.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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